Quarterly ResultMay 7, 2026, 04:09 PM
Tandem Diabetes Care Q1 Sales $247.2M; Reaffirms 2026 Guidance
AI Summary
Tandem Diabetes Care Inc. reported strong first-quarter 2026 financial results, achieving record pump shipments, sales, and gross margin. Worldwide sales increased 5% to $247.2 million, with gross margin improving to 55%. The company significantly reduced its GAAP net loss to $20.4 million from $130.6 million in the prior year. Tandem also made strategic advancements, including launching a pay-as-you-go reimbursement model in the U.S. and expanding Android compatibility for its Tandem Mobi system, while reaffirming its full-year 2026 financial guidance.
Key Highlights
- Worldwide sales increased 5% to $247.2 million in Q1 2026.
- US sales grew 7% to $160.8 million; International sales increased 3% to $86.4 million.
- Gross margin improved to 55%, up 480 basis points from Q1 2025.
- GAAP net loss was $20.4 million, significantly down from $130.6 million in Q1 2025.
- Achieved record first quarter pump shipments of over 29,000 worldwide.
- Launched pay-as-you-go reimbursement model in US pharmacy channel.
- Expanded Tandem Mobi connected care ecosystem with Android compatibility.
- Reaffirmed 2026 sales guidance of $1.065 billion to $1.085 billion.